228. 閉塞性細気管支炎 [臨床試験数:92,薬物数:125(DrugBank:34),標的遺伝子数:33,標的パスウェイ数:152

Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03315741
(ClinicalTrials.gov)
March 1, 20185/10/2017The Safety and Tolerability of Pirfenidone for BOS After HCTThe Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell TransplantationBronchiolitis Obliterans;Graft Vs Host DiseaseDrug: Pirfenidone 267 MG [Esbriet]Stanford UniversityGenentech, Inc.Recruiting18 YearsN/AAll30Phase 1United States
2EUCTR2014-002022-12-SE
(EUCTR)
06/08/201515/10/2014European Trial of Pirfenidone in BOS (EPOS).A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Esbriet
Product Name: Pirfenidone
INN or Proposed INN: PIRFENIDONE
Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone
Clinical Trials Unit, RigshospitaletNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 2Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden
3EUCTR2014-002022-12-NL
(EUCTR)
13/05/201503/11/2014European Trial of Pirfenidone in BOS (EPOS).A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Clinical Trials Unit, RigshospitaletNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
80 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noBelgium;Denmark;Germany;Netherlands;United Kingdom;Sweden
4NCT02262299
(ClinicalTrials.gov)
May 201521/9/2014European Trial of Pirfenidone in BOS, A European Multi-center StudyA European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-3 in Lung Transplant RecipientsDisorder Related to Lung Transplantation;CLAD, Bronchiolitis ObliteransDrug: Pirfenidone;Drug: PlaceboRigshospitalet, DenmarkNULLCompleted18 YearsN/AAll90Phase 2/Phase 3Belgium;Denmark;Germany;Netherlands;Norway;Sweden;United Kingdom
5EUCTR2014-002022-12-BE
(EUCTR)
10/03/201515/10/2014European Trial of Pirfenidone in BOS (EPOS).A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000015490;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Esbriet
Product Name: Pirfenidone
INN or Proposed INN: PIRFENIDONE
Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone
Clinical Trials Unit, RigshospitaletNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 2Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2014-002022-12-GB
(EUCTR)
06/01/201515/10/2014European Trial of Pirfenidone in BOS (EPOS).A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Clinical Trials Unit, RigshospitaletNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
90 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noBelgium;Denmark;Netherlands;Germany;United Kingdom;Sweden
7EUCTR2014-002022-12-DE
(EUCTR)
30/12/201421/10/2014European Trial of Pirfenidone in BOS (EPOS).A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Clinical Trials Unit, RigshospitaletNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
80 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noBelgium;Denmark;Netherlands;Germany;United Kingdom;Sweden
8EUCTR2014-002022-12-DK
(EUCTR)
15/12/201404/11/2014European Trial of Pirfenidone in BOS (EPOS).A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Esbriet
Product Name: Pirfenidone
INN or Proposed INN: PIRFENIDONE
Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone
Clinical Trials Unit, RigshospitaletNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Phase 2Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden